US Patent

US7776358 — Extended release venlafaxine besylate tablets

Formulation · Assigned to Synthon IP Inc · Expires 2028-05-16 · 2y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an extended release tablet formulation of venlafaxine besylate using a coating containing ammonio methacrylate copolymer(s).

USPTO Abstract

Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s).

Drugs covered by this patent

venlafaxine-besylate (VENLAFAXINE BESYLATE)

Patent Metadata

Patent number: US7776358
Jurisdiction: US
Classification: Formulation
Expires: 2028-05-16
Drug substance claim: No
Drug product claim: Yes
Assignee: Synthon IP Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.